Özmen, B. Et Al. 2007. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNFα, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis. European Cytokine Network , vol.18, no.3 , 148-153.

Özmen, B., KIRMAZ, C., Aydin, K., Kafesciler, S. O., Guclu, F., & HEKİMSOY, Z., (2007). Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNFα, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis. European Cytokine Network , vol.18, no.3, 148-153.

Özmen, Bilgin Et Al. "Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNFα, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis," European Cytokine Network , vol.18, no.3, 148-153, 2007

Özmen, Bilgin Et Al. "Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNFα, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis." European Cytokine Network , vol.18, no.3, pp.148-153, 2007

Özmen, B. Et Al. (2007) . "Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNFα, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis." European Cytokine Network , vol.18, no.3, pp.148-153.

@article{article, author={Bilgin Özmen Et Al. }, title={Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNFα, TGF-β1 and bone turnover markers in the treatment of postmenopausal osteoporosis}, journal={European Cytokine Network}, year=2007, pages={148-153} }